IMPORTANCE Persons with human immunodeficiency virus (HIV) that is treated with antiretroviral therapy have improved longevity but face an elevated risk of myocardial infarction (MI) due to common MI risk factors and HIV-specific factors. Despite these elevated MI rates, optimal methods to predict MI risks for HIV-infected persons remain unclear.
L ongevity among persons with human immunodeficiency virus (HIV) has increased dramatically owing to effective antiretroviral therapy (ART). [1] [2] [3] [4] There are more than 1.2 million and 35 million HIV-infected (HIV + ) adults in the United States and worldwide, respectively. These numbers are projected to grow and the aging HIV + population is increasingly at risk for noncommunicable disease-related morbidity and mortality. [5] [6] [7] Human immunodeficiency viruspositive persons have nearly twice the risk for myocardial infarction (MI) and greater risks for heart failure and sudden death compared with uninfected persons.
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The paradigm for preventing atherosclerotic cardiovascular disease (ASCVD)-which consists of nonfatal MI, coronary heart disease death, and stroke-is based on the principle that the intensity of prevention efforts should match patients' absolute risks. This requires accurate prediction of ASCVD risks. Although some studies have evaluated ASCVD risk estimation models in HIV + patients, these studies have generally been small and suboptimally assessed end points. [20] [21] [22] [23] One of the larger studies to date used a predominantly white cohort to derive the Data Collection on Adverse Events of Anti-HIV Drugs risk score, which incorporates specific antiretroviral agents but not race/ethnicity.
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The American College of Cardiology (ACC) and American Heart Association (AHA) 2013 Guideline on the Assessment of Cardiovascular Risk developed the Pooled Cohort Equations (PCEs) for 10-year ASCVD risk prediction to assist with ASCVD prevention decision making. 24 ,25 These equations were derived from more diverse population-based cohorts than prior ASCVD risk prediction tools. 26 The PCEs have not been evaluated in a large multicenter HIV cohort. Thus, the objectives of this study were to (1) evaluate PCE performance; (2) create dataderived, HIV-specific MI risk estimation models in a diverse, multicenter HIV cohort with rigorous MI adjudication; and (3) externally validate these models in a separate sample.
Methods

Study Population
We used the Centers for AIDS follow-up started 6 months after the initial CNICS study visit or the initial MI surveillance date. The outcome of interest was time to MI, and study participants were censored at 10 years if they died or were lost to follow-up. We performed sensitivity analyses of the PCEs in which we excluded all participants younger than 40 years at baseline (because the PCEs were originally intended for ASCVD risk assessment in those aged 40 to 79 years) and all participants with histories of cocaine use, given the association of cocaine with MI independent of cardiovascular disease risk factors.
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We evaluated PCE discrimination using the Harrell C statistic, and less than 0.70, 0.70 to 0.80, and greater than 0.80 were considered inadequate, acceptable, and excellent discrimination levels, respectively. 30 Model calibration was evaluated by the GND approach. 28,31 We analyzed our model's calibration on 4 levels using a hierarchy of increasing strictness (mean, weak, moderate, or strong calibration). 28 The first level (mean calibration or calibration in the large) measures whether the overall average predicted risk equals the observed event rate. 28 The second level (weak calibration) evaluates the slope and intercept of the models. There is better calibration between the model and the observed date the closer the slope is to 1 and the closer the intercept is to 0 because these 2 measures should map onto each other. 28 The third level evaluates whether observed and predicted event rates are equal for patient groups within the same general predicted risk strata; if so, the model is considered moderately calibrated. 28 The fourth level (strong calibration) requires predicted and observed event rates to correspond for every covariate pattern and is not possible when continuous predictors are used, or in sample sizes
After analyzing the PCEs, we created 2 risk scores using dataderived coefficients, aiming to improve on the ASCVD risk score. We included all variables from the ASCVD risk score, statin use, and HIV-specific variables (HIV viral load, CD4 lymphocyte count, antiretroviral therapy, and protease inhibitor use) as possible covariates. Single imputation was used for baseline variables (all with <50% missingness). We removed 1 site, the University of Alabama-Birmingham, from model derivation analyses to use it as a validation sample because of its demographic similarities to the US HIV + population (eMethods in the Supplement). 32 Data from the other 4 CNICS sites were randomly split into a training sample (to fit the models) and a holdout sample (to evaluate the models). The first new risk score (HIVMI-1) used lasso and ridge regression, while the second (HIVMI-2) used an average of Cox models to select variables and determine coefficients. Scores were evaluated in the validation cohort by Harrell C statistic and the aforementioned calibration hierarchy. 28 We also considered simpler methods than creating new data-derived risk scores. One supplementary analysis added 10 years to each participant's baseline PCE risk estimates to account for earlier MI occurrence in HIV, while the other multiplied MI rates by a data-derived multiplier.
Although the differentiation between type 1 MIs, which are caused by plaque rupture and thrombosis, and type 2 MIs, which result from supply-demand mismatch, is a strength of CNICS, we did not differentiate between MI types for this analysis because existing cardiovascular risk prediction models (including the PCEs) do not.
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Results
Demographic and Clinical Characteristics
Characteristics of participants with complete baseline covariate measurements (n=11 288; 247 persons with MI over a mean follow-up of 4.1 years) are shown in Table 1 . The cohort was relatively young at the baseline and most (70%) were taking antiretroviral therapy. Mean 10-year ASCVD risk estimates based on the PCEs were the highest for black men and the lowest for white women. Observed MI rates across demographic and clinical strata are shown in the eTable in the Supplement. Myocardial infarction rates were higher among black men and women, participants 40 years or older at baseline, and participants with greater HIV viral loads and lower CD4 lymphocyte counts. Racial differences in MI rates were largely driven 
Performance of ACC/AHA PCEs in CNICS
The PCEs discriminated ASCVD risk adequately overall (Harrell C statistic = 0.75; 95% CI, 0.71-0.78) and in most race and sex combinations ( Table 2 ). The PCEs were relatively well fitted in the overall cohort (Table 2 and Figure 1 ; slope = 0.815; intercept = 0.0015; GND test statistic = 13.1; P = .16), particularly for white men (Table 2 and Figure 2A ; slope = 0.857; intercept = 0.009; GND test statistic = 6.4; P = .50), meeting GND framework criteria for moderate calibration. However, the PCEs were not as well fitted for black men, black women, or white women (Table 2 and Figure 2B -D). Observed MI rates consistently exceeded predicted rates across the low-to-moderate risk spectrum (<10% predicted 10-year ASCVD risk), and this underprediction was particularly marked among black men ( Figure 2B ) and women ( Figure 2D ). In a sensitivity analysis excluding the 987 participants with histories of cocaine use, PCE performance was unchanged (data not shown). In separate supplementary analyses in which we added 10 years to all study participants' baseline PCE inputs and multiplied MI rates by a multiplier, discrimination was similar to the PCEs.
Derivation and Performance of New HIV-Specific Risk Scores
To create and derive new HIV-specific risk scores, we expanded the cohort from the other analyses to include all study participants (n = 19 829 [derivation sample that was split randomly into training and holdout samples, 15 849; validation sample, 3980]). Of the 15 849 participants not in the validation sample, 353 experienced MIs during a mean follow-up of 4.8 years.
The HIVMI-1 score included several HIV-specific variables and traditional ASCVD risk factors and adequately discriminated (Harrell C statistic = 0.72; 95% CI, 0.67-0.78) in the validation sample ( Figure 3A) . The HIVMI-2 score also incor- a GND test for calibration across deciles requires at least 2 events in each group; thus, the following risk deciles were collapsed together for the whole cohort: the 3 lowest risk deciles for white men; the 2 lowest risk deciles for black men; the 1 to 3, 4 to 6, and 7 to 9 lowest risk deciles for white women (plus a fourth group, the highest risk decile); and the 4 lowest risk deciles for black women. For the analyses of participants 40 years or older at baseline, the following risk deciles were collapsed together: none for white men, the 2 lowest risk deciles for black men, the 5 lowest and 5 highest risk deciles for white women (thus 2 groups total), and the 1 to 3 and 4 to 5 lowest risk deciles for black women.
porated several HIV-specific variables in addition to traditional ASCVD risk factors and adequately discriminated in the validation sample (Harrell C statistic = 0.73; 95% CI, 0.68-0.79) ( Figure 3B ). Both HIVMI-1 (slope = 0.40; intercept = 0.01; GND test statistic = 102.5; P < .001) and HIVMI-2 (slope = 0.50; intercept = 0.01; GND test statistic = 84.2; P < .001) exhibited substantially worse calibration than the PCEs. In a sensitivity analysis in the validation cohort only including participants with complete covariates, there was little change in HIVMI-1 and HIVMI-2 performance.
Discussion
The ACC/AHA PCEs exhibited acceptable discrimination and moderate calibration for predicting MIs among HIV + individuals in a multisite US HIV cohort with adjudicated MIs. Neither of the 2 data-derived models incorporating HIVspecific variables (HIVMI-I and HIVMI-2 scores) improved MI risk prediction in this population for several potential reasons. Traditional ASCVD risk factors are essential for risk estimation in general and remain important in an HIV setting; thus, the bar is high for new risk prediction tools incorporating new factors to predict ASCVD events. Although we know HIV-related factors (eg, HIV viral load and CD4 T-cell count) are associated with ASCVD, we know little about how strongly these factors or other HIV-associated biomarkers are associated with ASCVD. Researchers are interested in risk estimation models incorporating novel HIV-specific factors and biomarkers that reflect HIV-related ASCVD risks, and these may provide a future use for biorepository samples from HIV cohorts. Pooled Cohort Equation calibration was generally acceptable for the whole cohort. The whole cohort showed acceptable calibration-in-the-large, a slope near 1 between observed and expected, and an intercept near 0, and the GND goodness-of-fit test suggested moderate calibration. However, this high calibration level primarily applied to white men, as other sexes and races showed worse evidence of calibration. The slope between observed and expected events was particularly poor for women. The mismatch between the event rates predicted by the PCEs and observed MIs in CNICS was apparent for groups with risks at or near thresholds at which statins are often recommended in the general population (5%-10% 10-year predicted ASCVD risk). Participants for whom the PCEs predicted less than 10% 10-year ASCVD risk had consistently higher-than-predicted MI rates, while participants with greater than or equal to 10% predicted risk generally had lowerthan-predicted MI rates. The consistent underprediction of the PCEs over the lowto-moderate risk spectrum may have direct clinical implications. Current ACC/AHA guidelines recommend consideration of statin therapy for patients at greater than or equal to 7.5% (and in some cases, ≥5%) predicted 10-year ASCVD risk.
Thus, model calibration is more clinically meaningful in the low-to-moderate risk spectrum-near decision thresholds for statin use-than in the highest-risk groups, in which statin therapy's benefits most clearly outweigh the risks. Given our finding that HIV + patients at less than 10% predicted 10-year risk (by the PCEs) had consistently greater-than-expected event rates, it may be reasonable for clinicians to use the PCEs as a baseline gauge of what their patients' lowest predicted ASCVD risks are. For instance, if an HIV + patient's predicted 10-year ASCVD risk is 8%, our findings suggest that the patient's "true" risk is at least 8% and perhaps greater. This risk of at least 8% could guide clinician-patient consideration of cardiovascular disease-preventive therapy, keeping in mind potential interactions of these therapies (particularly statins) with antiretrovial therapy medications.
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There are several potential reasons for the overprediction of MI risk in the highest-risk groups. Patients with poorly controlled HIV may have high predicted MI risk and competing risks for noncardiovascular causes of death. Thus, they may have contributed many person-years at high predicted risk but died of noncardiovascular causes before theoretical MIs would have occurred, leading to overprediction of higher levels of risk. Survival bias may also contribute to this mismatch. Age is a strong contributor to MI risk, and older HIV-infected persons may have an elevated burden of traditional and HIV-related MI risk factors. While these factors would contribute to elevated predicted MI risk for older HIV-infected persons, they also would be likely to have survived longer with HIV and may therefore be likely to have greater care access, social support, or other unmeasured factors that could prevent incident MI. Finally, more patients at higher MI risk were taking statins, which decrease incident MI rates and may have decreased observed MI rates disproportionately in these higher-risk groups.
A caveat to the clinical applicability of these risk estimates is the relatively high number of type 2 MIs among HIV + people in CNICS. Type 2 MIs occur during systemic disease rather than inciting atherothrombotic events and may not be as effectively prevented by atheroprotective therapies such as statins. It is likely that type 2 MIs are more common for HIV + persons than uninfected persons because of their systemic disease (HIV) and susceptibility to states that trigger type 2 MIs, including infection and sepsis. Furthermore, the CNICS MI screening protocol incorporated cardiac biomarkers, which tend toward correctly identifying a high number of type 2 MIs that may not have been identified otherwise. Observed MI rates exceeded PCE-predicted rates most markedly for black men and women. Further, the proportion of MIs that were type 2 was also greater for black men and women than their white counterparts, and it is possible that this excess in type 2 MIs among black people drove much of this apparent underprediction of MI risk. However, distinguishing between types of MIs was beyond the scope of this study because previous risk estimation tools have not differentiated between MI types, and we wanted to assess the performance of the score on "any MI." Future analyses may compare risk prediction models incorporating all MIs vs only type 1 MIs. 35 It is noteworthy that strokes are a greater proportion of overall ASCVD for women, particularly black women. Thus, the MI rates we observed for women in CNICS may be lower than their overall ASCVD rates. Additionally, CNICS incorporated biomarkers into its MI screening protocol and likely captured more MIs than less-sensitive adjudication protocols in the cohorts from which the PCEs were derived. It is possible that this relative overassessment of MIs and definite underassessment of strokes resulted in ASCVD rates that would have been similar had the methods from these previous cohort studies been used to adjudicate MI and stroke in CNICS. Another limitation of this study was the relatively short mean follow-up, although many participants did have 10 years or greater of follow-up. We sought to address the relatively low number of people with follow-up to 10 years by using the GND approach. 31 Another study limitation was that only 5 of 8 CNICS sites were analyzed because of the availability of adjudicated MI data. These limitations were unavoidable and acceptable given the strengths of CNICS as a modern HIV clinical cohort with rigorous MI adjudication. Another complicating factor was the young age of the US HIV + population compared with cohorts used to develop the PCEs. Atherosclerotic cardiovascular disease risks increase with age and separation between people with higher and lower lifetime risks for ASCVD becomes more apparent; thus, discriminating between risk strata may be difficult in younger populations. Finally, few analyzed patients included in our analyses were taking statins. Statin use was more common for those with greater ASCVD risk and may have decreased observed MI rates for higher-risk deciles more than for lower-risk deciles.
Conclusions
Despite these limitations, this study suggests that the 2013 ACC/ AHA Risk Estimator's PCEs perform better than data-derived models incorporating HIV-specific variables at predicting MI risks for HIV + people. As longer-term follow-up data with more ASCVD events become available for HIV + people, studies should reassess whether data-derived, HIV-specific risk estimation models can improve ASCVD risk prediction over the PCEs in this population.
